Global CAR T Cell Therapy Competitive Landscape Report 2023: Insights About 250+ Companies and 500+ Drug Profiles - Product Type, Stage, Route of Administration, and Molecule Type - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "CAR T - Cell Therapy - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive insights about 250+ companies and 500+ drugs in CAR T - Cell Therapy Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

In January 2023, CARsgen Therapeutics had announced a collaboration with Huadong Medicine to commercialize zevorcabtagene autoleucel (zevor-cel), CT053, in mainland China. Under the collaboration, Huadong Medicine will have the exclusive right to commercialize CARsgen's CT053 in mainland China. According to the deal, CARsgen will receive $29.7m (RMB200m) in upfront payment and is also eligible for up to $152.4m (RMB1,025m) in regulatory and commercial milestones.

In December 2022, Arcellx, Inc. announced a global strategic collaboration to co-develop and co-commercialize Arcellx's lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Currently in Phase 2 clinical development, CART-ddBCMA is an investigational cell therapy product comprising autologous T cells that have been genetically modified to target multiple myeloma. CART-ddBCMA utilizes Arcellx's novel D-Domain binder. Kite and Arcellx will jointly advance the CART-ddBMCA asset.

In December 2022, CARsgen Therapeutics Holdings Limited announced that at the 2022 American Society of Hematology (the "ASH") Annual Meeting, the Company presented a poster with the results of the phase I/II LUMMICAR STUDY 1 clinical trial of zevorcabtagene autoleucel. Results for the 14 subjects treated in phase I of LUMMICAR STUDY 1 showed a well-tolerated safety profile, plus deep and durable responses with an objective response rate (ORR) of 100% and a complete response/stringent complete response (CR/sCR) rate of 78.6%.

In October 2022, CARsgen Therapeutics Holdings Limited announced that the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for zevorcabtagene autoleucel for the treatment of relapsed and/or refractory multiple myeloma (R/R MM). The acceptance of the NDA was based on data from an open-label, single arm Phase I/II clinical trial (LUMMICAR STUDY 1 [Protocol number CT053-MM-01]) in China. Study results showed that zevor-cel has excellent safety and efficacy profiles. Zevor-cel also represents a promising treatment option for patients with high-risk disease.

In August 2022, Poseida Therapeutics, Inc. announced it has entered into a broad strategic collaboration and license agreement with Roche, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies. The global collaboration covers the research and development of multiple existing and novel "off-the-shelf" cell therapies against targets in multiple myeloma, B-cell lymphomas and other hematologic indications.

Key Questions Answered

• How many companies are developing CAR T - Cell Therapy drugs?
• How many CAR T - Cell Therapy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of CAR T - Cell Therapy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the CAR T - Cell Therapy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for CAR T - Cell Therapy and their status?
• What are the key designations that have been granted to the emerging and approved drugs?

Key Players

• Cartesian Therapeutics
• CASI Pharmaceuticals/Juventas Cell Therapy
• Novartis
• Poseida Therapeutics
• Shanghai Unicar-Therapy Bio-medicine Technology
• JW Therapeutics
• Gilead Sciences
• Cellular Biomedicine Group
• Gracell Bio
• Mustang Bio
• Servier
• iCell Gene Therapeutics
• Kecellitics Biotech Company Ltd
• Gilead sciences
• Miltenyi Biotec
• Nanjing KAEDI Biotech
• Liminatus Pharma
• Yake Biotechnology
• AffyImmune Therapeutics
• Fundamenta Therapeutics
• Actinium Pharmaceuticals
• Allogene Therapeutics
• Celyad Oncology
• Maxcyte
• Sorrento Therapeutics
• Cellular Biomedicine Group
• Sorrento Therapeutics
• Shanghai GeneChem Co., Ltd.
• Sensei Biotherapeutics
• Obsidian Therapeutics
• Beijing Biohealthcare Biotechnology Co. Ltd.
• Eutilex/Utilities
• Precigen, Inc.
• Miltenyi Biomedicine
• Wugen
• WindMIL Therapeutics
• MiNK Therapeutics
• CiMaas
• Catamaran Bio
• Innate Pharma
• Healios
• Chimeric Therapeutics
• ONK Therapeutics
• Neukio Biotherapeutics
• Exacis Biotherapeutics
• Editas Medicine

Key Products

• Descartes-11
• CNCT19
• CTL119
• P-BCMA-101
• CD19/CD20/CD22/CD30 CAR T-cell therapy
• JWCAR029
• KTE-X19
• Ciltacabtagene autoleucel
• CD20-CD19 Bispecific CAR
• GC027
• MB-103
• UCART19
• BCMA-CD19 cCAR T cells therapy
• Anti CD19 CART
• Human anti-CD19
• CD20 CAR T cells
• Anti-CD19 Chimeric Antigen Receptor T cells (KD-019 CAR-T)
• GUCY2C-Targeted CAR-T Cells
• CD19 CAR T-cells
• AIC100
• ThisCART22
• Iomab-ACT Program
• ALLO-501
• CYAD-211
• MCY-M11
• PSMA CAR-T -cell immunotherapy
• Anti-CD20 CAR
• c-KIT CAR-T
• BCK - CART
• EGFRv III-CART
• SNS-723
• cytoDRiVE technology based therapy
• CD30-targeted Chimeric Antigen Receptor T cell therapy
• Solid cancer specialized CAR-T
• MVR CAR-T
• PRGN-3007
• PRGN-3008
• huBCMA
• MB-CART 2219.1
• WU-CART-002
• CAR-MILs
• Stromal target-CAR-iNKT
• CIM 301
• CAT-179
• IPH65
• IPH62
• IPH64
• HLCN 061
• CHM 0301
• ONKT105
• ONKT106

Research programme: NK cell therapeutics

• iPSC-CAR-NK
• ExaCAR-NK
• ExaNK
• ExaCAR-T
• EDIT 301

For more information about this report visit https://www.researchandmarkets.com/r/pvpi9u

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900